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Point-of-care biomarkers in asthma management: time to move forward
To the Editor,
The Global Initiative for Asthma (GINA) report was primarily intended as a strategy 
document and not a clinical guideline. However, the 2014 update moved the report 
towards a "practical, clinical practice-centred document", and has in many countries 
formed a basis for national guidelines. A possible limitation of the GINA report is its 
primary focus on evidence coming from randomised controlled trials, potentially leading 
to the omission of clinically important data coming from real-life and observational studies, 
and in conclusions based on highly-selected asthmatic patients, fulfilling strict study 
inclusion criteria. 
The interest in biomarkers for clinical decision making has grown exponentially over the 
last 10-15 years in parallel to increasing evidence that asthma is a heterogeneous 
condition with different underlying pathophysiology, and with different responses to 
treatment1. Biomarkers can help identify these different phenotypes and endotypes, and 
subsequent treatment response to standard treatment or targeted therapeutic options 
with biologicals. In this capacity, they complement symptom scoring and lung function 
measurement in asthma management. For example, fractional exhaled nitric oxide 
(FeNO), which is a marker of type-2 driven inflammation within the bronchial mucosa2, 
has been shown to be a much stronger predictor of corticosteroid responsiveness in 
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such as spirometry3. Another reason for the increased interest in asthma biomarkers – 
evidenced by approximately 5,000 scientific articles published on exhaled NO – is the 
extensive development of regulator-approved devices for quick and non-invasive FeNO 
measurement4. Likewise, blood eosinophil (B-Eos) count, a biomarker that has been 
widely available for quite some time although scarcely used, is presently undergoing a 
renaissance in interest including the development of point-of-care devices5. Ample 
evidence exists of a strong association between elevated blood eosinophils and 
increased risk of asthma exacerbations1. Interestingly, simultaneously elevated FeNO 
and B-Eos count add the risk of asthma attacks and asthma morbidity, independently of 
each other6. Thus, although elevated B-Eos count and FeNO often occur together, they 
represent different parts of the type-2 inflammatory pathway, with FeNO being particularly 
linked to the IL-4/IL-13 pathway2. Some confounders have been recognized for FeNO, 
primarily smoking, rhinovirus infections and nitrate intake, but measures to handle these 
in the clinic have been suggested4. Little is known about confounders for B-Eos count, 
except a marked circadian variation.
Despite the emerging data on the utility of B-Eos count and an increasing number of 
studies investigating the applicability of FeNO measurement in routine clinical 
management of asthma4, the incorporation of biomarkers into guidelines remains slow. 
The latest 2019 GINA report (https://ginasthma.org/gina-reports), recommends the use of 
FeNO to aid phenotyping of severe asthma and to differentiate COPD from asthma, but 
not as an aid to diagnosis or management of less severe asthma. Furthermore, it 
suggests that elevated FeNO in preschool children with recurrent coughing and wheezing 
predicts asthma later in the life. In contrast, lung function measurements, which are of 
little use in distinguishing between asthma endotypes, have been adopted and are 
routinely featured in all guidelines.
In 2014, the National Institute for Health and Care Excellence (NICE) in the United 
Kingdom published a guidance document for the clinical use of FeNO measurement in 
patients with asthma (http://www.nice.org.uk/dg12/evidence). This thorough health 
technology assessment, incorporating a detailed cost-effectiveness analysis, identified 
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asthma. In November 2017, NICE published their new clinical guidelines focusing on the 
diagnosis, monitoring and chronic asthma management 
(https://www.nice.org.uk/guidance/ng80). These guidelines were developed using a 
pragmatic approach, with the consideration of both real-life and observational studies as 
well as more strict randomized controlled trials. The conclusions were to recommend 
FeNO measurement and spirometry to be used as initial assessments in all patients in 
whom asthma is suspected, and propose FeNO measurement to be considered in the 
management of patients with asthma who remain symptomatic despite inhaled 
corticosteroid treatment. 
 
Thus, NICE and GINA have come to substantially different conclusions on the utility of 
FeNO in clinical practice. This demonstrates that examination of evidence by two 
different expert groups can yield different recommendations at the same time. Further 
explanations for the different conclusions drawn may reflect different perspectives of the 
respective experts: UK-focused in the case of NICE versus GINA’s more global 
perspective. It is also possible that potentially practical advantages of FeNO 
measurement (for example ease of use, reproducibility, cost-effectiveness, at least in the 
UK context) and availability of detailed practice guidelines may have been weighted 
differently by the GINA and NICE committees. 
We hope that the contrasting guidelines will stimulate further clinical research on the use 
of simple and accessible point-of-care biomarkers (such as FeNO and blood eosinophils) 
for determining the inflammatory endotype, their link to targeted treatment 
responsiveness and the potential to assess future risk of exacerbations and lung function 
decline. It is of note that large pragmatic studies in primary care have shown that FeNO-
guided management reduces the rate of asthma exacerbations7, is cost effective and 
improves asthma control while minimising corticosteroid use8. Furthermore, FeNO 
strongly predicted symptomatic response to inhaled corticosteroids in those with unclear 
evidence of asthma in terms of bronchial reversibility in a randomised trial set in both 
primary and secondary care9. Additional real-life studies would be useful to complement 
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In conclusion, there is an increasing  need for clinical biomarkers to better stratify patients 
according to their inflammatory phenotype or endotype. FeNO measurement shows 
promise in the diagnosis and management of asthma, particularly to predict potential 
response to inhaled corticosteroid treatment, and, in combination with B-Eos count, to 
assess future risk. Furthermore, both biomarkers should be used to indicate 
responsiveness to new type-2 targeted treatment (dupilumab) in severe asthma, 
according to the European Medicines Agency (https://www.ema.europa.eu/en/news/new-
add-treatment-patients-severe-asthma), and they will be useful in the future development 
of other biological drugs in asthma. To enable adequate inclusion of biomarkers in 
asthma guidelines for the broad benefit of patients and society, guidelines should 
consider all available evidence, including both real-life studies and randomised controlled 
trials.
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